Lamotrigine, Mexiletine Show Similar Benefits for Nondystrophic Myotonias
By Lori Solomon HealthDay Reporter
WEDNESDAY, Oct. 9, 2024 -- Improvements in nondystrophic myotonias symptoms are similar for lamotrigine and mexiletine, according to a study published in the October issue of The Lancet Neurology.
Vinojini Vivekanandam, Ph.D., from the Centre for Neuromuscular Disorders at the National Hospital for Neurology and Neurosurgery in London, and colleagues randomly assigned 53 adults with genetically confirmed symptomatic nondystrophic myotonia to receive either mexiletine for eight weeks followed by lamotrigine for eight weeks or lamotrigine followed by mexiletine with a seven-day washout period in between.
The researchers found that the mean interactive voice response stiffness score after treatment with mexiletine was 2.54 versus 2.77 with lamotrigine (mean mexiletine-lamotrigine difference, −0.23; 95 percent confidence interval, −0.63 to 0.17). For both groups, the most common adverse event was indigestion-reflux (eight participants, 208 participant-days receiving mexiletine; seven participants, 130 participant-days receiving lamotrigine). There were no serious adverse events.
"Approximately one in 17 people in the U.K. have a rare disease and the majority have no treatment. Many are neurological diseases and rarity makes clinical trials to develop treatments very difficult," Vivekanandam said in a statement. "The trial results are very exciting and important for patients with this muscle channelopathy."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Study Compares Benefits, Harms of Treatments for Chronic Hives
WEDNESDAY, July 23, 2025 -- Omalizumab and remibrutinib may be the most effective treatments for reducing hives, itch, and swelling with chronic urticaria, according to a study...
USPSTF Guidelines of Little Value for Estimating Preeclampsia Risk in Those at Moderate Risk
WEDNESDAY, July 23, 2025 -- Moderate U.S. Preventive Services Task Force (USPSTF) preeclampsia risk factors have little value for estimating the risk for preeclampsia, according...
Endocrine Society, July 12-15
The annual meeting of the Endocrine Society (ENDO 2025) was held from July 12 to 15 in San Francisco, attracting more than 7,000 participants, including clinicians, academicians...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.